Dolgit® 800
coated tablets
![DolgitRR 800](javascript:obrazek_big("http://promedcs.cz//en/../img/baleni/600_dolgit800(1).jpg", "en"); "DolgitRR 800")
- Manufacturer:
- Dolorgiet Pharmaceuticals, St.Augustin/Bonn, SRN.
- Sole distributor for the Czech Republic:
- PRO.MED.CS Praha a.s.
- Marketing authorisation holder:
- Dolorgiet Pharmaceuticals, St.Augustin/Bonn, SRN.
- Composition:
- Ibuprofenum 800 mg in 1 coated tablet.
- Indication group:
- nonsteridal antirheumatic, analgesic
The following information is for health professionals only.
READ CAREFULLY THIS NOTICE!
Characteristics:
Ibuprofen has an antiphlogistic, analgesic and antipyretic effect. The mechanism of its pharmacological effect is based on the inhibition of biosynthesis of prostaglandines and other mediators. Dolgit® 800 (Ibuprofen) tbl. reduces local and overall symptoms of inflammation (oedema, pain, increased temperature) and helps to restore the function of affected joints and muscles.
Indications:
Rheumatic and degenerative arthropathy. Myalgia and myositis. Bursitis and tendovaginitis. Lumbago, cervicobrachial syndrome. Traumatic damage of joints (luxation, haemorrhage, dislocation) and muscles. Wricking of muscle by sport or other physical activity. Painful postoperative conditions. Dysmenorrhea.
Contraindications:
Hypersensitivity to ibuprofen or other nonsteroidal antiphlogistic agents. Active gastric and duodenal ulcer. Disorders of haematopoiesis and haemocoagulation. Children under 18 years. In patient with congestive heart insufficiency, arterial hypertension, severe renal and hepatic function disorders, bronchial asthma and during pregnancy and lactation Dolgit® 800 can be used only if necessary.
Undesirable effects:
Dolgit® 800 tbl. Is usually well tolerated. In the course of administration gastric and intestinal dyspepsia (nausea, pyrosis, painful epigastric pressure, diarrhoea), headache, weakness, dizziness, blurred vision, disorders of haematopoiesis, somnolence or increased irritability, allergic exanthema, water retention with oedema may occur. Rarely bleeding into the digestive tract.
Interactions:
During concomitant administration of Dolgit® 800 (Ibuprofen) tbl. and digoxin, phenytoin, lithium, probenecid, sulfinpyrazone, methotrexate, diuretics and antihypertensives, the effects of drugs are mutually potentiated. Concomitant administration of Dolgit® 800 (Ibuprofen) tbl. with glucocorticoids, acetylsalicylic acid and other antiphlogistics leads to a dangerous increase in the risk of gastrointestinal tract damage (severe bleeding into the GIT). Potentiation of the hypoglycaemic effect of sulphonylurea oral antidiabetic agents is also clinically significant.
Caution:
Dolgit® 800 tbl. can negatively influence activities requiring higher attention, motoric co-ordination and quick decision-making. Use of alcohol in any form during Dolgit® 800 tbl. therapy considerably increases the risk of undesirable effects. During Dolgit® 800 tbl. therapy, it is necessary to check urine, blood count and faeces for occult bleeding once a month.
Dosage:
The usual dose of Dolgit® 800 tbl. is 1 coated tablet maximally 3 times a day (administered in 8 hourly intervals). Daily dose 2400 mg should not be exceeded. Coated tablets are swallowed unchewed with a sufficient amount of water.
Package:
20, 50 or 100 coated tablets of 800 mg.
For greater details about the preparation see the product data summary.
Date of latest revision of the text: February 20, 2002.
The preparation is available on medical prescription only.